P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine
ECCO'20 Vienna
2020
P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
ECCO'20 Vienna
2020
P599 Trimester exposure and pregnancy outcomes in women exposed to golimumab: Results from the company pharmacovigilance database
ECCO'20 Vienna
2020
P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
ECCO'20 Vienna
2020
P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study
ECCO'20 Vienna
2020
P605 Eight-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
ECCO'20 Vienna
2020
P606 Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn’s disease
ECCO'20 Vienna
2020
P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis
ECCO'20 Vienna
2020
P609 An IBD dermatology multidisciplinary clinic: A single tertiary centre experience
ECCO'20 Vienna
2020
P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic
ECCO'20 Vienna
2020
P611 Provision of care for pregnant women with IBD in the UK - the current landscape
ECCO'20 Vienna
2020
P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study
ECCO'20 Vienna
2020
P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience
ECCO'20 Vienna
2020